Bausch + Lomb Corp Dossier - Source-backed chat

Bausch + Lomb Corp

BLCONYSE

SectorHealth Care

IndustryMedical Instruments & Supplies

Beta (adjusted)0.71

Intrinsic Value $20.75median of 3 methodsbased on filings through 30 Jun 2026

Market Price $17.00Price as of 30 Sep 2026

UndervaluedIntrinsic value is 22% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $6.1B

Enterprise Value $10.8B

Shares Outstanding 356.7M diluted

Moat Rating None

Next Earnings Date28 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Bausch + Lomb (BLCO) presents a compelling fundamental turnaround story driven by strong execution in its dry eye portfolio (MIEBO and Xiidra) and robust innovation in its contact lens pipeline (Project Halo). However, the stock remains constrained by its complex corporate structure, with parent company Bausch Health (BHC) retaining an approximate 87% controlling stake. This overhang, combined with high leverage and ongoing separation uncertainties, limits near-term multiple expansion despite strong operational performance.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets12 analysts · as of 18 Aug 2026

Low · most bearish analyst$16.00

Mean target$18.63

High · most bullish analyst$23.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects execution risks in the surgical segment reorganization, pricing pressure from new dry eye market entrants, and prolonged delays in the BHC spin-off. High interest expenses continue to weigh on GAAP profitability, leading to persistent net losses and potential downward revisions of valuation multiples.

Base CaseCentral scenario

The base case assumes steady mid-single-digit top-line growth (5-7% constant currency) in line with raised FY2026 guidance, supported by stable contact lens market share and moderate margin expansion. Valuation multiples remain capped near historical averages due to the persistent BHC ownership overhang and slow deleveraging progress.

Bull CaseUpside scenario

The bull case is driven by rapid market adoption of premium dry eye treatments (MIEBO and Xiidra), which are transitioning from launch phase to high-margin growth mode. Additionally, successful execution of the 'Vision 27' efficiency program and the launch of Project Halo bioactive lenses by 2028 could drive EBITDA margins toward the company's 23% target, unlocking significant valuation upside.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial momentum in dry eye franchise with MIEBO (+33% YoY) and Xiidra (+30% YoY) driving high-margin growth.
Robust product pipeline including Project Halo bioactive contact lenses and ELIOS MIGS device targeting large addressable markets.
Raised FY2026 guidance reflecting strong operational execution and 178 bps of adjusted EBITDA margin expansion in Q1 2026.

Key Investment Risks

Corporate overhang from parent company Bausch Health (BHC) holding an approximate 87% controlling stake.
High leverage and interest burden limiting GAAP net income and free cash flow generation.
Intense competitive pricing pressure in the contact lens and dry eye markets.

Thesis Invalidation Triggers

Failure to achieve the FY2026 adjusted EBITDA guidance of 1.01 billion to 1.06 billion USD.
A formal cancellation or indefinite postponement of the BHC separation plan.
Significant market share loss in the daily silicone hydrogel contact lens segment to competitors.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.